Gene therapy for carcinoma of the breast genetic ablation strategies

Breast Cancer Research

Volumn 2, Issue 1, 2000, Pages 45-49

  Curiel, D T ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense; Dominant negative; Gene therapy; Oncogene; Ribozyme

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; CYCLIN D1; DNA; ESTROGEN RECEPTOR; ONCOPROTEIN; RIBOZYME;

BREAST CARCINOMA; CELL CYCLE; CELL DAMAGE; CELL GROWTH; CELL TRANSFORMATION; CLINICAL TRIAL; DNA VECTOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; KNOCKOUT GENE; ONCOGENE; PROTO ONCOGENE; REVIEW;

BREAST NEOPLASMS; FEMALE; GENE THERAPY; HUMANS;

EID: 0034467003     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr28     Document Type: Review

References (54)

1. Gene therapy for carcinoma of the breast
2. Gene therapy approaches for treatment of cancer
3. Gene therapy strategies for novel cancer therapeutics
4. Gene therapy for cancer therapeutics
5. Chromosomal abnormalities in human breast cancer
6. Tumor suppressor genes and their roles in breast cancer
7. Somatic genetic changes in human breast cancer
8. Hypermutability and mismatch repair deficiency in RER+ tumor cells
9. Suppressor gene alterations in the colorectal adenomia-carcinoma sequence
10. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinoma
11. The p53 tumor suppressor gene in breast cancer
12. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer
13. Allelotyping of ductal carcinoma in situ of the breast: Deletion of loci on 8p, 13q, 16q, 17p, 17q
14. Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast
15. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions
16. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes
17. Clonal chromosome abnormalities in human breast carcinomas. Thirty four cases with metastatic disease
18. Clonal chromosome abnormalities in human breast carcinomas. Twenty eight cases with primary disease
19. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization
20. Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection
21. Chromosome analysis of 97 primary breast carcinomas: Identification of eight karyotypic sub-groups
22. The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies
23. Tumor-specific inhibition of lymphoma growth by an antisense oligonucleotide
24. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer
25. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA
26. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct
27. 1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells
28. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
29. Expression of transforming growth factor α antisense mRNA inhibits the estrogen-induced production of TGFα and estrogen-induced proliferation of estrogen-responsive human breast cancer cells
30. Reduction of erbB-2 gene product in mammary carcinoma cell lines by erbB-2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides
31. Repressed expression of the HER-2/c-ErbB-2 proto-oncogene by the adenovirus E1A gene products
32. Mechanisms of c-erbB-2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products
33. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A
34. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice
35. A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer
36. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization
37. Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant
38. Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth
39. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation
40. Intracellular single-chain antibody directed against erbB2 down regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB-2 overexpressing cancer cell lines
41. Targeted tumor cell killing via an intracellular antibody directed against the erbB-2
42. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis
43. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2
44. Single-chain antibody-mediated intracellular retention of erbB-2 impairs neu differentiation factor and epidermal growth factor signalling
45. Intracellular expression of single chain antibodies reverts erbB-2 transformation
46. A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow
47. Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation
48. Improving adeno-viral vectors for cancer gene therapy
49. Strategies to adapt adenoviral vectors for gene therapy applications: Targeting and integration
50. Targeted adenoviral vectors for cancer gene therapy
51. The promise of cancer gene therapy
52. Gene therapy for breast cancer
53. Breast cancer: Cell and gene therapy
54. Gene therapy strategies for carcinoma of the breast